Abstract
Gamma-herpesvirus infections are regulated by both CD4+ and CD8+ T cells. However clinical disease occurs mainly in CD4+ T cell-deficient hosts. In CD4+ T cell-deficient mice, CD8+ T cells control acute but not chronic lung infection by Murid Herpesvirus-4 (MuHV-4). We show that acute and chronic lung infections differ in distribution: most acute infection was epithelial, whereas most chronic infection was in myeloid cells. CD8+ T cells controlled epithelial infection, but CD4+ T cells and IFNγ were required to control myeloid cell infection. Disrupting the MuHV-4 K3, which degrades MHC class I heavy chains, increased viral epitope presentation by infected lung alveolar macrophages and allowed CD8+ T cells to prevent disease. Thus, viral CD8+ T cell evasion led to niche-specific immune control, and an essential role for CD4+ T cells in limiting chronic infection.
Author summary
Gamma-herpesviruses chronically infect most people. While infection is usually asymptomatic, disease occurs if the immune system is weakened. Understanding how immune control normally works should provide a basis for preventing disease. In mice, CD8+ T cells can control acute gamma-herpesvirus infection but not chronic infection. We show that acute and chronic infections involve different cell types. CD8+ T cells controlled epithelial cell infection, which predominated acutely, but they could not control chronic macrophage infection unless viral immune evasion was disabled. Instead CD4+ T cells were required. Thus, viral evasion made host defence cell type-specific: CD8+ T cells controlled epithelial cell infection; CD4+ T cells controlled macrophage infection; and comprehensive control required both T cell subsets.
Introduction
Herpesviruses chronically infect immunocompetent hosts. CD4+ and CD8+ T cells both help to contain these infections, but disease occurs mainly when CD4+ T cells are lacking [1], implying that they have particular importance. Among the gamma-herpesviruses, CD4+ T cell deficiency leads Epstein-Barr virus (EBV) to cause lymphoproliferative disease and oral hairy leukoplakia, a virus-productive epithelial lesion [2]; it leads the Kaposi's Sarcoma-associated Herpesvirus (KSHV) to cause endothelial cell proliferation with inflammation and viral lytic gene expression [3]; and it leads MuHV-4 to replicate chronically in the lungs [4]. Thus the pathologies of CD4+ T cell-deficient hosts vary, but increased lytic infection is a common theme.
Gamma-herpesviruses characteristically persist in lymphocytes. EBV, KSHV and MuHV-4 all persist in B cells. However to reach B cells then re-emerge to reach new hosts they must also infect other cell types. EBV emerging from plasma cells [5] reaches the saliva via epithelial cells [6]. The normal association of plasma cells with mucosal epithelial cells provides a basis for virus transfer. How EBV reaches naive B cells is less well understood, as they have little direct communication with mucosal epithelia. Antigen presentation by myeloid cells provides a potential route to naive B cells. KSHV can infect many cell types [7], including myeloid cells [8]; EBV colonization of NK cell and T cell cancers [9] suggests a broader tropism than is usually evident in vitro; and MuHV-4, after epithelial host entry [10, 11], reaches B cells via dendritic cells [12]. Myeloid cell infection also features prominently in acute MuHV-4 colonization of splenic B cells [13–15]. Thus while only modestly efficient in vitro [16] and hard to detect in the long-term [13], myeloid cell infection plays a key role in MuHV-4 tropism.
Acute MuHV-4 lung infection is controlled mainly by CD8+ T cells [17]. They also help to control splenic B cell infection [18], and macrophage infection after peritoneal challenge [19]. β2-microglobulin-deficient BALB/c mice show a 3-fold increase in lymphoma incidence after MuHV-4 infection [20]. However β2-microglobulin deficiency impairs more than just than CD8+ T cell function, for example it reduces serum IgG [21]. Therefore the increased lymphoma incidence was not just CD8+ T cell dependent. Moreover few if any lymphoma cells showed evidence of MuHV-4 infection [20], and no lymphomas were seen in MuHV-4-infected β2M-/- C57BL/6 [22] or 129 mice [20]. Inbred mice are prone to lymphomagenesis by strain-polymorphic endogenous retroviruses [23], and gamma-herpesviruses can transactivate retroviruses [24]. Therefore the ontogeny of the lymphomas remains unclear. The most obvious consequence of CD8+ T cell deficiency for MuHV-4 is increased lytic infection [22]. While cancers are the most harmful outcome of EBV infection, T cell deficiency again mainly increases lytic infection [25].
CD4+ T cell-deficient mice also show more lytic infection. However unlike CD8+ T cell-deficient mice, and despite maintaining strong anti-viral CD8+ T cell responses [26–28], they suffer a wasting disease [4]. Anti-MuHV-4 antibody responses help to contain infection [29] and depend on CD4+ T cells [30], but a lack of antibody alone does not explain the disease of CD4+ T cell-deficient mice, as B cell-deficient mice survive [31]. Acutely CD4+ T cells suppress MuHV-4 replication independently of B cells, with an important role for interferon-γ (IFNγ) [32, 33], so their effector function may also be important for long-term MuHV-4 control.
Why CD8+ T cells alone fail to control MuHV-4 is important to understand because they are a therapeutic focus for EBV. CD8+ T cell evasion is a near universal characteristic of mammalian herpesviruses. While its molecular mechanisms have been studied extensively, its impact on infection is less well understood. The MuHV-4 K3 degrades MHC class I (MHC I) [34] and the transporter associated with antigen processing (TAP) [35]. K3 disruption impairs virus-driven lymphoproliferation [36]. We show that in chronic infection, K3 protects lung macrophages against CD8+ T cells and so makes CD4+ T cells essential to prevent disease.
Results
Different cell types support acute and chronic MuHV-4 lung infections
MuHV-4 replicates chronically in MHC class II (MHC II)-deficient (IA-/-) C57BL/6 mice, which lack classical CD4+ T cells [4]. Intranasal (i.n.) BAC-derived MuHV-4 reached similar peak titers in the lungs of IA-/- and wild-type control mice (WT, IA+/-) at day (d) 5 post-infection, but then maintained higher titers in IA-/- mice (Fig 1A). The main cell populations of the lung alveoli are type 1 epithelial cells (AEC1), which have a characteristically flattened shape with a large surface area for gas exchange, and express podoplanin (PDP); type 2 AEC (AEC2), which express surfactant proteins; and alveolar macrophages (AM), which phagocytose inhaled debris and express CD68. MuHV-4 entering the lungs binds to AEC1 and is then captured by AM [11]. Subsequent replication in AM allows spread back to AEC1 and makes them the main site of acute virus production. At d5, immunostaining for viral lytic antigens showed mainly AEC1 infection in both WT and IA-/- mouse lungs (Fig 1B and 1C; S1 Fig; S2 Fig). By d9, WT lungs contained few infected cells. IA-/- lungs contained significantly more (p<0.01), and most of these were AM. AM infection remained detectable at d30 in IA-/- (Fig 1B and 1D; S3 Fig) but not WT mice. Few AEC2 or lung B cells expressed viral lytic antigens. Thus WT mice resolved acute AEC1 infection, while in IA-/- mice it evolved into a chronic infection of AM.
CD4+ T cell-depleted C57BL/6 mice showed a similar picture (Fig 1E and 1F). The virus titers in depleted mouse lungs were equivalent to those of undepleted controls at d5, then higher at d12 (Fig 1E). Lung sections showed mainly AEC1 infection at d5, and mainly AM infection at d12 (Fig 1F). We did not see evidence of chronic epithelial cell infection, as reported for B cell-deficient mice [37]. Ongoing myeloid cell infection may seeds epithelial infection in some settings, but the main cell type supporting chronic lung infection in CD4+ T cell-deficient mice was myeloid.
CD8+ T cells control AEC1 infection
MuHV-4 causes disease more readily in BALB/c than in C57BL/6 mice [20], with acute protection being CD8+ T cell-dependent [17]. We tested whether BALB/c mice also showed CD4+ T cell-dependent myeloid infection control (Fig 2). Live imaging of i.n. luciferase+ MuHV-4 showed CD4+ T cell depletion significantly increasing lung and nose infections at d7 and d9 (Fig 2A). CD8+ T cell depletion had significantly more effect, and dual depletion had more effect still. CD8+ T cell depletion also increased colonization of the superficial cervical lymph nodes (SCLN), which drain the upper respiratory tract, while CD4+ T cell depletion reduced SCLN colonization, consistent with the amplification of B cell infection in lymphoid tissue being CD4+ T cell-dependent [38]. D9 virus titers in lungs and noses (Fig 2B) matched the luciferase signals, with dual depleted > CD8+ T cell depleted > CD4+ T cell depleted > undepleted controls. Thus acutely, when epithelial infection predominated, CD8+ T cells contributed more than CD4+ T cells to controlling virus replication in both the upper and lower respiratory tract.
Immunostaining infected BALB/c lungs at d9 (Fig 2C–2E) showed significantly more AEC1 than AM infection in all groups except that depleted of CD4+ T cells, which showed significantly more AM infection. Epithelial and fibroblast infections were consistently more virus-productive than myeloid cell infection in vitro (Fig 2F), and the higher virus titers of mice with more AEC1 infection were consistent with AEC1 producing more virus acutely than AM. Thus, CD8+ T cells appeared to be more important than CD4+ T cells for acute infection control because they targeted a more immediately virus-productive cell type—AEC1—while a lack of CD4+ T cells increased AM infection.
CD4+ T cells and IFNγ control MuHV-4 replication in the lungs
In mice lacking B cells and CD8+ T cells, IFNγ is required for acute infection control [32, 33], suggesting that it mediates the anti-viral effect of CD4+ T cells. It also inhibits ex vivo MuHV-4 reactivation from peritoneal macrophages [39]. In otherwise immunocompetent BALB/c mice, IFNγ neutralization increased d9 lung virus titers significantly more than did CD4+ T cell depletion (Fig 3A), and increased both AM and AEC1 infections (Fig 3B and 3C), implying that it also mediated other anti-viral effects. Again CD4+ T cell depletion decreased MuHV-4 colonization of lymphoid tissue, whereas IFNγ neutralization increased it (Fig 3A).
CD4+ T cells, CD8+ T cells and NK cells all produce IFNγ. When CD8+ T cells were eliminated, CD4+ T cell depletion increased virus titers and AM infection significantly more than did IFNγ neutralization (Fig 3D and 3E). Therefore while IFNγ was an important CD4+ T cell-mediated defence, it was not the only one and it contributed also to CD8+ T cell-mediated defence. NK cell depletion does not affect the course of MuHV-4 lung infection in otherwise immunocompetent mice [40], but increases LN infection by MuHV-4 inoculated into footpads [41]. In C57BL/6 mice NK cells did not make a significant contribution to infection control in lungs at d10, making it unlikely that they were a significant source of IFNγ in this setting (Fig 4A). They did contribute to infection control in noses (Fig 4B). Here NK cell depletion increased virus titers regardless of whether CD4+ T cells were depleted. Therefore CD4+ T cells and NK cells functioned as independent defences.
CD4+ T cells control MuHV-4 replication in MHC II+ cells
CD4+ and CD8+ T cells differ in both target cell recognition and predominant effector functions: CD8+ act mostly via perforin and granzymes, while IFNγ is a key effector for CD4+ T cells [42]. Thus, CD4+ T cell-dependent myeloid infection control could have reflected either that only CD4+ T cells efficiently recognized infected myeloid cells (via MHC II), or that only IFNγ was able to control their infection. To explore these possibilities we tracked the infection of MHC II+ lung cells (Fig 5). In naive lungs, 1/3 of MHC II+ cells were CD11c+ AM or dendritic cells, and 2/3 were surfactant protein C precursor (SPC)+ AEC2 (Fig 5A). After MuHV-4 infection, most MHC II+ cells (>70%) were SPC-, presumably reflecting myeloid cell recruitment and MHC II up-regulation. Almost all MuHV-4+ cells (>95%) were SPC-, that is myeloid rather than AEC2 (Fig 5B).
Again we depleted CD8+ T cells as a source of IFNγ, then compared additional CD4+ T cell depletion with IFNγ neutralization. CD4+ T cell depletion increased the number of infected MHC II+ lung cells, while IFNγ neutralization gave only a non-significant increase (Fig 5C and 5D). Most AM express CD11c [43, 44]. Both IFNγ neutralization and CD4+ T cell depletion increased significantly the number of CD11c+MHC II+ infected cells. CD4+ T cell depletion but not IFNγ neutralization significantly increased the number of CD11c-MHC II+ infected cells (Fig 5E and 5F). SPC+ infection remained rare (Fig 5G), so CD11c-MHC II+MHV+ cells were presumably infected CD11c- AM or infiltrating monocytes. Thus, CD4+ T cell depletion increased MuHV-4 infection of MHC II+ lung myeloid cells, and IFNγ neutralization reproduced much of this effect, consistent with IFNγ production being an important CD4+ T cell effector function. However the greater effect of CD4+ T cell depletion than IFNγ neutralization on lung myeloid cell infection implied that target cell recognition was the key parameter, rather than susceptibility to IFNγ.
The MuHV-4 K3 prevents AM infection control by CD8+ T cells
The importance of CD4+ T cell recognition for AM infection control implied poor CD8+ T cell recognition. Virus-specific CD8+ T cells were evidently functional in IA-/- mice, as they controlled AEC1 infection; and myeloid cells are normally good CD8+ T cell targets [45]. However the MuHV-4 K3 degrades MHC I and TAP. To test whether K3 compromised CD8+ T cell recognition of AM, we exposed AM to K3+ or K3- viruses, then measured epitope presentation to a MuHV-4-specific CD8+ T cell hybridoma (Fig 6A). K3 disruption significantly increased hybridoma stimulation by both WT and IA-/- AM.
To establish whether better CD8+ T cell recognition of infected AM translated into better infection control, we infected IA-/- mice with K3+ or K3- MuHV-4. K3+ viruses caused significantly more disease (weight loss and general ill health requiring euthanasia) (Fig 6B) and reached higher titers in both lungs and spleens (Fig 6C). When CD8+ T cells were depleted, K3+ and K3- viruses reached equivalent titers (Fig 6D). Immunostaining IA-/- lung sections at infection d10 (Fig 6E and 6F) showed that K3- viruses lacked the chronic AM infection of WT MuHV-4. Infectious center assays of AM recovered by lung washout (Fig 6G) confirmed greater infection by K3+ viruses. Therefore K3 limited CD8+ T cell-mediated control of MuHV-4 replication in lung myeloid cells.
Discussion
Gamma-herpesviruses establish chronic, low-level transmission with generally few symptoms. Immunodeficiencies shift this equilibrium towards greater viral replication and disease. The key parameters of disease control in humans have been hard to define. Thus, anti-viral therapies have remained largely empirical. Our analysis of murine infection showed cell type-specific immune control. In mice lacking CD4+ T cells, CD8+ T cells still controlled epithelial infection. We did not see extensive B cell infection, presumably due to a lack of CD4+ T cell-dependent B cell proliferation [38]. However myeloid cell colonization, which is normally transient, became chronic and caused disease. This disease depended on CD8+ T cell evasion by the MuHV-4 K3: when K3 was disrupted, CD8+ T cells achieved long-term infection control and CD4+ T cells were not required.
Why did K3 protect infected macrophages and not epithelial cells against CD8+ T cells? K3 stabilization by tapasin [46] titrates its expression to the cellular capacity for antigen presentation, for example overcoming induction by IFNγ [35]. However immune evasion only raises the threshold for epitope presentation: peptides competing strongly for the few remaining MHC I complexes can still be recognized. Infected epithelial cells produced more virus than infected myeloid cells, implying that they produced more viral peptides, making break-through viral epitope presentation more likely. Cell type differences in susceptibility to CD8+ T cell attack are also possible. The faster clearance of pro-lytic MuHV-4 mutants from the lungs despite faster spread in vitro [47, 48] suggests that more indolent gamma-herpesvirus infections generally constitute more difficult immune targets. Myeloid cell infection is a common characteristic of lymphotropic viruses [49, 50], and MuHV-4 myeloid cell infection caused chronic disease despite limited virus production. Therefore poorly lytic infection should not exclude myeloid cell infection from consideration as a source of human gamma-herpesvirus-driven disease.
While IA-/- mice make large CD8+ T cell responses to MuHV-4 [26], the non-uniformity of in vivo infection means that large immune responses are not always the most effective responses. For example MuHV-4-infected mice normally mount a large CD8+ T cell response to viral reactivation from latency in B cells [51]; yet if MHC I epitope presentation is enforced during viral episome maintenance [52], a relatively small CD8+ T cell response essentially abolishes latent B cell infection and hence also reactivation. The large acute CD8+ T cell responses to EBV lytic antigens [53] analogously imply a failure to suppress virus-driven lymphoproliferation. In IA-/- mice CD8+ T cells kept AEC1 infection in check, but they did not shut down virus production by K3-protected myeloid cells. This required CD4+ T cells. Thus without CD4+ T cells, myeloid infection could constantly re-seed epithelial infection.
CD4+ T cells may be difficult for MuHV-4 to evade because it needs them to drive infected B cell proliferation. Also MHC II presents mainly exogenous antigens, so the presenting cells need not be infected, making them difficult to target. While CD4+ T cells have limited cytotoxic capacity, they can trigger apoptosis via tumor necrosis factor receptors and fas, activate myeloid cells to reduce their susceptibility to infection [54], and through cytokine signalling repress viral lytic gene expression directly [55]. Thus, there are abundant opportunities for CD4+ effector T cells to restrict MuHV-4 replication.
Most studies of anti-viral immunity have averaged outcomes across whole organs. Direct visualization is revealing additional complexity. For example CD8+ T cells combat cutaneous vaccinia virus by killing infected monocytes rather than keratinocytes [56]. Direct visualization revealed that immune evasion makes MuHV-4 control cell type-specific: CD8+ T cells controlled epithelial infection, and CD4+ T cells controlled myeloid infection. Thus CD4+ and CD8+ T cells co-operated, but less through classical help than through recognizing distinct components of a complex infection. Such niche-specific immune function suggests that single component vaccines eliciting mainly one effector class might only ever have partial efficacy against complex viruses; multi-component vaccines that prime complementary defences may be necessary for full protection.
Materials and methods
Mice
Adult C57BL/6, BALB/c, and C57BL/6 back-crossed IA-/- mice [57] were infected i.n. with MuHV-4 (104 p.f.u.) under isoflurane anaesthesia. Luciferase+ infection was imaged by peritoneal (i.p.) injection of D-luciferin (2mg/mouse, Pure Science) and charge-coupled camera scanning (IVIS spectrum, Xenogen). IFNγ was neutralized by i.p. mAb XMG1.2 (200μg/mouse/48h). CD4+ and CD8+ T cells were depleted by i.p. mAbs GK1.5 and 2.43 (200μg/mouse/48h, from 96h before infection). NK cells were depleted with NK1.1-specific mAb PK-136 (200μg/mouse/48h, from 48h before infection). Antibodies were from Bio X Cell. T cell subset depletion, measured by flow cytometry of spleen cells with antibodies to a distinct CD4 epitope (rat mAb RM4-4), and to CD8β (rat mAb H35-17.2) and was >95% complete. CD4+ T cell-depleted mice further lacked detectable MuHV-4-specific serum IgG by ELISA (S4 Fig). NK cell depletion, monitored by flow cytometric staining of spleen cells for CD49d with mAb DX5, was >90% complete. Statistical comparisons were by Student's 2-tailed unpaired t test unless otherwise stated.
Ethics statement
All experiments were approved by the University of Queensland Animal Ethics Committee in accordance with the Australian code for the care and use of animals for scientific purposes, from the Australian National Health and Medical Research Council (project 301/13).
Cells
Peritoneal macrophages were recovered by peritoneal lavage. After discarding non-adherent cells, the remainder were >80% F4/80+ by flow cytometry. Lung macrophages were recovered by bronchio-alveolar lavage and were >70% CD11c+ by flow cytometry. These cells, BHK-21 fibroblasts (American Type Culture Collection (ATCC) CCL-10), RAW-264 monocytes (ATCC TIB-71), NMuMG epithelial cells (ATCC CRL-1636), the 49100.2 T cell hybridoma [58], and mouse embryo fibroblasts were grown in Dulbecco’s Modified Eagle’s Medium with 2mM glutamine, 100IU/ml penicillin, 100μg/ml streptomycin, and 10% fetal calf serum (complete medium).
Viruses
Luciferase+ [59] and GFP+ [60] MuHV-4, a K3- mutant and its revertant [36] and an independent K3 mutant (K3-I) [54] were propagated in BHK-21 cells. Infected cell supernatants were cleared of debris by low speed centrifugation (200 x g, 5 min). Cell-free virions were then concentrated by ultracentrifugation (35,000 x g, 1.5h). To titer infectious virus, freeze-thawed samples were plated on BHK-21 cells (plaque assay); to titer total reactivatable MuHV-4, live cells were plated (infectious center assay) [60]. After 2h the cells were overlaid with complete medium plus 0.3% carboxymethylcellulose, cultured for 4d (37°C in complete medium) then fixed with 1% formaldehyde and stained with 0.1% toluidine blue.
Immunostaining
Organs were fixed in 1% formaldehyde / 10mM sodium periodate / 75mM L-lysine (18h, 4°C), equilibrated in 30% sucrose (24h, 4°C), then frozen in OCT. 6μm sections were air-dried, washed 3x in PBS, blocked with 0.3% Triton X-100 / 5% donkey serum (1h, 23°C), then incubated (18h, 4°C) with combinations of antibodies to GFP (rabbit or goat pAb), CD68 (rat mAb, FA-11) (AbCam), B220 (rat mAb RA3-6B2), CD4 (rat mAb GK1.5), CD11c (hamster mAb N418, Abcam), MHC II (rat mAb M5/114, Serotec), SPC (goat pAb; Santa Cruz Biotechnology), podoplanin (goat pAb, R&D Systems), and MuHV-4 (rabbit pAb). The MuHV-4-immune serum was raised by 2x subcutaneous inoculation of rabbits with MuHV-4 virions (109 p.f.u.). Like previously described immune sera [61] it recognizes a range of virion proteins by Western blot, including the products of ORF4 (gp70), M7 (gp150) and ORF65 (p20). Sections were washed 3×, incubated (1h, 23°C) with combinations of Alexa568-donkey anti-rat IgG pAb, Alexa488 or Alexa647-donkey anti rabbit IgG pAb, Alexa 647-goat anti-hamster IgG pAb (AbCam), and Alexa488-donkey anti-goat IgG pAb (Life Technologies), then washed 3×, mounted in Prolong Gold with DAPI (Life Technologies), and imaged with a Zeiss LCM510 confocal microscope.
Antigen presentation
Lung macrophages were infected or not with MuHV-4 (3 p.f.u./cell, 4h), washed, then incubated (18h, 37°C) in complete medium with 49100.2 T cells, which recognize an immunodominant, H2Db-restricted MuHV-4 epitope and express β-galactosidase (β-gal) from an NFAT-responsive promoter [58]. To assay β-gal the cells were washed in PBS and lysed in PBS / 5mM MgCl2 / 1% NP-40 / 0.15μM chlorophenol-red-beta-D-galactoside (CPRG, Merck Biosciences). 595nm absorbance was read after 2–4h.
ELISA
MuHV-4 virions in 0.05% Triton-X100 / 50mM sodium carbonate pH = 8.5, were coated (18h, 4°C) onto Maxisorp ELISA plates (Nalge Nunc). The plates were washed x3 in PBS / 0.1% Tween-20, blocked with 1% bovine serum albumin / PBS / 0.1% Tween-20, incubated with 3-fold serum dilutions (1h, 23°C), washed x4 in PBS / 0.1% Tween-20, incubated (1h, 23°C) with alkaline phosphatase-conjugated goat anti-mouse IgG-Fc pAb (Sigma Chemical Co.), washed x5, and developed with nitrophenylphosphate substrate (Sigma). Absorbance was read at 405nm (Biorad).
Supporting information
Acknowledgments
We thank Professor Geoff Hill for providing IA-/- mice, and Dr. Samita Andreansky for helpful discussion.
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
The work was funded by the Australian National Health and Medical Research Council (https://www.nhmrc.gov.au/), via Project grants 1064015, 1060138, and 1079180; the Australian Research Council (www.arc.gov.au/) via Future Fellowship FT130100138; and the Belgian Science policy office (https://www.belspo.be) via collaborative grant Belvir. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Carneiro-Sampaio M, Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun. 2007; 75: 1545–1555. doi: 10.1128/IAI.00787-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Cruchley AT, Williams DM, Niedobitek G, Young LS. Epstein-Barr virus: biology and disease. Oral Dis. 1997; 3 Suppl 1:S156–163. [DOI] [PubMed] [Google Scholar]
- 3.Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol. 2006; 1: 273–296. doi: 10.1146/annurev.pathol.1.110304.100133 [DOI] [PubMed] [Google Scholar]
- 4.Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med. 1996; 184: 863–871. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005. January;79(2):1296–307. doi: 10.1128/JVI.79.2.1296-1307.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jiang R, Scott RS, Hutt-Fletcher LM. Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42. J Virol. 2006. July;80(14):7281–3. doi: 10.1128/JVI.00497-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bechtel JT, Liang Y, Hvidding J, Ganem D. Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol. 2003; 77: 6474–6481. doi: 10.1128/JVI.77.11.6474-6481.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Blasig C, Zietz C, Haar B, Neipel F, Esser S, et al. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol. 1997; 71: 7963–7968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.George LC, Rowe M, Fox CP. Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. Curr Hematol Malig Rep. 2012; 7: 276–284. doi: 10.1007/s11899-012-0136-z [DOI] [PubMed] [Google Scholar]
- 10.Milho R, Frederico B, Efstathiou S, Stevenson PG. A heparan-dependent herpesvirus targets the olfactory neuroepithelium for host entry. PLoS Pathog. 2012; 8: e1002986 doi: 10.1371/journal.ppat.1002986 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lawler C, Milho R, May JS, Stevenson PG. Rhadinovirus host entry by co-operative infection. PLoS Pathog. 2015; 11:e1004761 doi: 10.1371/journal.ppat.1004761 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Gaspar M, May JS, Sukla S, Frederico B, Gill MB, et al. Murid herpesvirus-4 exploits dendritic cells to infect B cells. PLoS Pathog. 2011; 7:e1002346 doi: 10.1371/journal.ppat.1002346 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Marques S, Efstathiou S, Smith KG, Haury M, Simas JP. Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes. J Virol. 2003; 77: 7308–7318. doi: 10.1128/JVI.77.13.7308-7318.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Weck KE, Kim SS, Virgin HW, Speck SH. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J Virol. 1999; 73: 3273–3283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Frederico B, Chao B, May JS, Belz GT, Stevenson PG. A murid gamma-herpesviruses exploits normal splenic immune communication routes for systemic spread. Cell Host Microbe. 2014; 15: 457–470. doi: 10.1016/j.chom.2014.03.010 [DOI] [PubMed] [Google Scholar]
- 16.Frederico B, Milho R, May JS, Gillet L, Stevenson PG. Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4. PLoS Pathog. 2012; 8: e1002935 doi: 10.1371/journal.ppat.1002935 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ehtisham S, Sunil-Chandra NP, Nash AA. Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol. 1993; 67: 5247–5252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Marques S, Alenquer M, Stevenson PG, Simas JP. A single CD8+ T cell epitope sets the long-term latent load of a murid herpesvirus. PLoS Pathog. 2008; 4: e1000177 doi: 10.1371/journal.ppat.1000177 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Tibbetts SA, van Dyk LF, Speck SH, Virgin HW. Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J. Virol. 2002; 76: 7125–7132. doi: 10.1128/JVI.76.14.7125-7132.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Tarakanova VL, Suarez F, Tibbetts SA, Jacoby MA, Weck KE, et al. Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J Virol. 2005; 79: 14668–14679. doi: 10.1128/JVI.79.23.14668-14679.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ardeniz Ö, Unger S, Onay H, Ammann S, Keck C, et al. β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. J Allergy Clin Immunol. 2015; 136: 392–401. doi: 10.1016/j.jaci.2014.12.1937 [DOI] [PubMed] [Google Scholar]
- 22.Stevenson PG, Cardin RD, Christensen JP, Doherty PC. Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. J Gen Virol. 1999; 80: 477–483. doi: 10.1099/0022-1317-80-2-477 [DOI] [PubMed] [Google Scholar]
- 23.Risser R, Horowitz JM, McCubrey J. Endogenous mouse leukemia viruses. Annu Rev Genet. 1983; 17: 85–121. doi: 10.1146/annurev.ge.17.120183.000505 [DOI] [PubMed] [Google Scholar]
- 24.Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001; 15: 579–589. [DOI] [PubMed] [Google Scholar]
- 25.Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999; 190: 567–576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Stevenson PG, Belz GT, Altman JD, Doherty PC. Virus-specific CD8+ T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice. Proc Natl Acad Sci USA. 1998; 95: 15565–15570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Belz GT, Stevenson PG, Castrucci MR, Altman JD, Doherty PC. Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice. Proc Natl Acad Sci USA. 2000; 97: 2725–2730. doi: 10.1073/pnas.040575197 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Belz GT, Liu H, Andreansky S, Doherty PC, Stevenson PG. Absence of a functional defect in CD8+ T cells during primary murine gammaherpesvirus-68 infection of I-Ab-/- mice. J Gen Virol. 2003; 84: 337–341. doi: 10.1099/vir.0.18821-0 [DOI] [PubMed] [Google Scholar]
- 29.Kim IJ, Flaño E, Woodland DL, Blackman MA . Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol. 2002; 168: 3958–3964. [DOI] [PubMed] [Google Scholar]
- 30.Stevenson PG, Doherty PC. Non-antigen-specific B-cell activation following murine gamma-herpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo. J Virol. 1999; 73: 1075–1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Usherwood EJ, Stewart JP, Robertson K, Allen DJ, Nash AA. Absence of splenic latency in murine gammaherpesvirus 68-infected B cell-deficient mice. J. Gen. Virol. 1996; 77: 2819–2825. doi: 10.1099/0022-1317-77-11-2819 [DOI] [PubMed] [Google Scholar]
- 32.Christensen JP, Cardin RD, Branum KC, Doherty PC. CD4+ T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. Proc Natl Acad Sci USA. 1999; 96:5135–5140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sparks-Thissen RL, Braaten DC, Hildner K, Murphy TL, Murphy KM, et al. CD4 T cell control of acute and latent murine gammaherpesvirus infection requires IFN gamma. Virology 2005; 338: 201–208. doi: 10.1016/j.virol.2005.05.011 [DOI] [PubMed] [Google Scholar]
- 34.Boname JM, Stevenson PG. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 2001; 15: 627–636. [DOI] [PubMed] [Google Scholar]
- 35.Boname JM, de Lima BD, Lehner PJ, Stevenson PG. Viral degradation of the MHC class I peptide loading complex. Immunity 2004; 20: 305–317. [DOI] [PubMed] [Google Scholar]
- 36.Stevenson PG, May JS, Smith XG, Marques S, Adler H, et al. K3-mediated evasion of CD8+ T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol. 2002; 3: 733–740. doi: 10.1038/ni818 [DOI] [PubMed] [Google Scholar]
- 37.Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T. 1998. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med. 1998; 187: 1941–1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Usherwood EJ, Ross AJ, Allen DJ, Nash AA. Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J. Gen. Virol. 1996; 77: 627–630. doi: 10.1099/0022-1317-77-4-627 [DOI] [PubMed] [Google Scholar]
- 39.Steed A, Buch T, Waisman A, Virgin HW. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol. 2007; 81: 6134–6140. doi: 10.1128/JVI.00108-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL. Control of murine gammaherpesvirus infection is independent of NK cells. Eur J Immunol. 2005; 35: 2956–2961. doi: 10.1002/eji.200526245 [DOI] [PubMed] [Google Scholar]
- 41.Lawler C, Tan CS, Simas JP, Stevenson PG. Type I Interferons and NK Cells Restrict Gammaherpesvirus Lymph Node Infection. J Virol. 2016; 90: 9046–9057. doi: 10.1128/JVI.01108-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002; 20: 323–370. doi: 10.1146/annurev.immunol.20.100201.131730 [DOI] [PubMed] [Google Scholar]
- 43.Guth AM, Janssen WJ, Bosio CM, Crouch EC, Henson PM, Dow SW. Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2009; 296: L936–L946. doi: 10.1152/ajplung.90625.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Farrell HE, Lawler C, Oliveira MT, Davis-Poynter N, Stevenson PG. Alveolar Macrophages Are a Prominent but Nonessential Target for Murine Cytomegalovirus Infecting the Lungs. J Virol. 2015; 90: 2756–2766. doi: 10.1128/JVI.02856-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Harty JT, Bevan MJ. CD8 T-cell recognition of macrophages and hepatocytes results in immunity to Listeria monocytogenes. Infect Immun. 1996; 64: 3632–3640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Lybarger L, Wang X, Harris MR, Virgin HW, Hansen TH. Virus subversion of the MHC class I peptide-loading complex. Immunity 2003; 18: 121–130. [DOI] [PubMed] [Google Scholar]
- 47.May JS, Coleman HM, Smillie B, Efstathiou S, Stevenson PG. Forced lytic replication impairs host colonization by a latency-deficient mutant of murine gamma-herpesvirus-68. J Gen Virol. 2004; 85: 137–146. doi: 10.1099/vir.0.19599-0 [DOI] [PubMed] [Google Scholar]
- 48.Rickabaugh TM, Brown HJ, Martinez-Guzman D, Wu TT, Tong L, et al. Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection. J Virol. 2004; 78: 9215–9223. doi: 10.1128/JVI.78.17.9215-9223.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Roy S, Wainberg MA. Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J Leukoc Biol. 1988; 43: 91–97. [DOI] [PubMed] [Google Scholar]
- 50.Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR. Critical role of dendritic cells in mouse mammary tumor virus in vivo infection. J Virol. 2007; 81: 3769–3777. doi: 10.1128/JVI.02728-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Stevenson PG, Belz GT, Altman JD, Doherty PC. Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine gamma-herpesvirus infection. Eur J Immunol. 1999. 29: 1059–1067. doi: 10.1002/(SICI)1521-4141(199904)29:04<1059::AID-IMMU1059>3.0.CO;2-L [DOI] [PubMed] [Google Scholar]
- 52.Bennett NJ, May JS, Stevenson PG. Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol. 2005. 3: e120 doi: 10.1371/journal.pbio.0030120 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, Bell JI, Rickinson AB, McMichael AJ. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996; 2: 906–911. [DOI] [PubMed] [Google Scholar]
- 54.Smith CM, Gill MB, May JS, Stevenson PG. Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells. PLoS One 2007; 2: e1048 doi: 10.1371/journal.pone.0001048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Goodwin MM, Canny S, Steed A, Virgin HW. Murine gammaherpesvirus 68 has evolved gamma interferon and stat1-repressible promoters for the lytic switch gene 50. J Virol. 2010; 84: 3711–3717. doi: 10.1128/JVI.02099-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadán JG, et al. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe 2013; 13: 155–168. doi: 10.1016/j.chom.2013.01.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science. 1991; 253: 1417–1420. [DOI] [PubMed] [Google Scholar]
- 58.Liu L, Flaño E, Usherwood EJ, Surman S, Blackman MA, Woodland DL. Lytic cycle T cell epitopes are expressed in two distinct phases during MHV-68 infection. J. Immunol. 1999; 163: 868–874. [PubMed] [Google Scholar]
- 59.Milho R, Smith CM, Marques S, Alenquer M, May JS, et al. In vivo imaging of murid herpesvirus-4 infection. J Gen Virol. 2009; 90: 21–32. doi: 10.1099/vir.0.006569-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.May JS, Stevenson PG. Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralization. J Gen Virol. 2010; 91: 2542–2552. doi: 10.1099/vir.0.023085-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Gillet L, Adler H, Stevenson PG. Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection. PLoS One. 2007; 2: e347 doi: 10.1371/journal.pone.0000347 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.